Actively Recruiting
Brain Imaging Biomarkers in Patients With Brain Metastasis
Led by University Health Network, Toronto · Updated on 2026-03-05
90
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A biomarker is a measurable indicator of the severity or presence of some disease state. In this study, brain metastases patients who will be receiving radiation treatment, will undergo CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) scans prior to and after radiation treatment to measure these biomarkers. This is a single-center phase II study to validate the predictive abilities of biomarkers, in terms of determining how patients will respond to radiation treatment.
CONDITIONS
Official Title
Brain Imaging Biomarkers in Patients With Brain Metastasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy proven primary malignancy with brain imaging consistent with brain metastases
- At least one brain lesion larger than 1 cm without signs of hemorrhage on imaging
- Age over 18 years
- Planned to receive radiation therapy for brain metastases
- Ability and willingness to provide written informed consent
You will not qualify if you...
- Prior whole brain radiotherapy
- Prior radiosurgery to the brain lesion being studied
- Unable to undergo contrasted MRI for any reason
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Health Network
Toronto, Ontario, Canada, L4W4C2
Actively Recruiting
Research Team
D
David Shultz, M.D., Ph. D
CONTACT
C
Catherine Coolens, Ph. D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here